Molecular Diagnostic Laboratory (MDL)
MDL is fully accredited by the College of American Pathologist (CAP). It is operated by certified personnel and qualified doctors with expertise in molecular pathology who ensure the accuracy of test results and the effectiveness of the lab.
MDL commits to quality service by strictly adhere to clinical laboratory regulation.
- MDL provides fast and accurate results for existing diagnostic tests.
- MDL implements and develops high-complexity tests to meet clinical needs.
- MDL collaborates with clinical research.
MDL performs nucleic acid-based test of human sample to provide reliable test results to clinicians.
- Hybrid Capture 2 High-Risk HPV DNA Test – FDA approved In Vitro nucleic acid hybridization assay with signal amplification for the qualitative detection of thirteen high-risk types of human papillomavirus (HPV) DNA in cervical specimens. It is generally accepted that these viruses are predominantly sexually transmitted and that high-risk HPV types are a major recognized risk factor for the development of cervical cancer. In conjunction with clinical information derived from other diagnostic and screening tests, physical examinations and full medical history, HPV DNA Test is a great valuable contribution in patient-management decisions.
- Aptima Combo2 CT/GC Assay – FDA-approved target amplification nucleic acid probe test that utilizes target capture for the in vitro qualitative detection and differentiation of ribosomal RNA from Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC). CT and GC infections are two of the most common sexually transmitted infections worldwide. This test aids in the diagnosis of chlamydial and/or gonococcal urogenital disease. This test can be done on a wide variety of patients’ samples including endocervical, vaginal, male urethral swab specimens, PreservCyt liquid Pap specimens, and in female and male urine samples from symptomatic and asymptomatic individuals.
- TruGene HIV-1 Genotyping: FDA-approved method for use in detecting HIV-1 genomic mutations (in the protease and part of the reverse transcriptase regions of HIV-1) that confer resistance to specific types of antiretroviral drugs, as an aid in monitoring and treating HIV infection. This provides clinicians with a genetic map, which may guide physicians in making more informed treatment decisions, thereby improving patient outcome.
For more information please contact:
Yu Bai, MD. PhD.
Medical Technologist III
Molecular Diagnostics Laboratory